|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02162 KEYMED BIO-B
Nominal 
78.450 +9.950 (+14.526%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 498,752 | 812.095% | 428,124 | 354,095 | 100,063 | 110,269 |
| Cost of Sales | (33,476) | 796.039% | (12,200) | (36,878) | (2,585) | (17,200) |
| Gross Profit | 465,276 | 813.273% | 415,924 | 317,217 | 97,478 | 93,069 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | (3,480,294) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | (37,932) | |
| Share of Results of Asso. & JCEs | (566) | -66.667% | (5,256) | (4,748) | (9,711) | (719) | |
| Profit / (Loss) before Taxation | (75,664) | -77.108% | (508,647) | (356,188) | (303,597) | (3,892,632) | |
| Taxation | (3,135) | -48.429% | (6,260) | (1,597) | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (44) | -69.014% | (334) | (1,572) | (4,518) | 5,323 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (78,843) | -76.587% | (515,241) | (359,357) | (308,115) | (3,887,309) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (32,405) | -1.081% | (69,869) | (71,087) | (45,919) | 4,120 |
| Depreciation & Amortisation | 48,885 | 5.501% | 93,228 | 69,161 | 36,123 | 21,019 |
| Directors' Emoluments | -- | -- | 11,191 | 11,143 | 10,208 | 7,728 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -30.000 | -76.744% | -197.000 | -137.000 | -118.000 | -2,417.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (3.014) | (1.162) | (1.539) | (1.334) |
| NBV per share ($) | 10.694 | -- | 8.846 | 10.675 | 11.941 | 13.052 |
| Remarks: | Real time quote last updated: 05/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -78,843 |
| %Change | -76.587% |
| EPS / (LPS) | RMB -0.300 |
| NBV Per Share (¥) | RMB 10.694 |